Last updated: April 16, 2024
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Overall Status: Active - Not Recruiting
Phase
N/A
Condition
Colon Cancer; Rectal Cancer
Colorectal Cancer
Rectal Cancer
Treatment
bupivacain+dexmedetomidine
Bupivacain
Clinical Study ID
NCT06370949
2024-01/17
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- colorectal cancer diagnosis
- undergoing colorectal cancer surgery
Exclusion
Exclusion Criteria:
- allergic reaction to local anesthetics
- bleeding anomalies
- infection in TAP block area
Study Design
Total Participants: 84
Treatment Group(s): 2
Primary Treatment: bupivacain+dexmedetomidine
Phase:
Study Start date:
May 01, 2024
Estimated Completion Date:
November 30, 2024
Study Description
Connect with a study center
Turkey Dr.Abdurrahman Yurtaslan Ankara Oncology Train and Research Hospital
Ankara, Cankaya 06110
TurkeySite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.